Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday

Hoth Therapeutics (NASDAQ:HOTH) is anticipated to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Hoth Therapeutics to post earnings of ($0.39) per share for the quarter.

Hoth Therapeutics Stock Performance

Shares of NASDAQ:HOTH opened at $1.04 on Thursday. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $3.80. The company has a market capitalization of $7.18 million, a PE ratio of -0.79 and a beta of 0.84. The company has a 50 day moving average price of $1.22 and a two-hundred day moving average price of $1.01.

Analyst Ratings Changes

Several brokerages have commented on HOTH. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of Hoth Therapeutics in a research note on Monday, March 10th. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a research report on Thursday, January 23rd.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.